Randomized Trialhigh evidence
Phase 2b Trial of a NaV1.8 Inhibitor for Acute Pain.
The New England journal of medicine·July 30, 2026·PMID 42526026
Why it mattersA non-opioid analgesic targeting peripheral NaV1.8 channels could address acute pain while minimizing opioid exposure and central side effects. High-dose LTG-001 reduced pain and opioid consumption, offering a potential alternative for multimodal postoperative pain management.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled